EPANED® (enalapril maleate) Oral Solution 1 mg/mL, the First and Only FDA-Approved Enalapril Oral Solution for the Treatment of Pediatric Hypertension in Patients Older than 1 Month, is Now Available

January 10, 2017
Silvergate Pharmaceuticals, Inc.

EPANED® (enalapril maleate) Oral Solution 1 mg/mL, the First and Only FDA-Approved Enalapril Oral Solution for the Treatment of Pediatric Hypertension in Patients Older than 1 Month, is Now Available

Denver, January 10, 2017 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that EPANED® Oral Solution, the first and only FDA-approved enalapril oral solution, is now available for ordering. Read full article “EPANED® (enalapril maleate) Oral Solution 1 mg/mL, the First and Only FDA-Approved Enalapril Oral Solution for the Treatment of Pediatric Hypertension in Patients Older than 1 Month, is Now Available”

Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older, is Now Available

October 26, 2016
Silvergate Pharmaceuticals, Inc.

Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older, is Now Available

Denver, October 26, 2016 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that Qbrelis™ (lisinopril) oral solution, the first and only FDA-approved lisinopril oral solution, is now available for ordering.  Qbrelis™ is indicated for the treatment of hypertension (high blood pressure) in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction (heart attack) in adults.1

Read full article “Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older, is Now Available”

FDA Approves Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older

July 29, 2016
Silvergate Pharmaceuticals, Inc.

FDA Approves Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older

Denver, July 29, 2016 — Silvergate Pharmaceuticals, Inc. (www.silvergatepharma.com), leader in the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Qbrelis™ (Lisinopril) Oral Solution, the first and only FDA-approved Lisinopril oral solution. Qbrelis™ is indicated for the treatment of hypertension (high blood pressure) in adult patients and pediatric patients 6 years of age and older, adjunct therapy for heart failure, and treatment of acute myocardial infarction in adults.1 Read full article “FDA Approves Qbrelis™, the First and Only Lisinopril Oral Solution 1 mg/mL for Pediatric Patients 6 Years of Age and Older”

FDA Approves 2 New Indications for Epaned®, the First and Only Enalapril Powder for Oral Solution

September 8, 2014
Silvergate Pharmaceuticals, Inc.

FDA Approves 2 New Indications for Epaned®, the First and Only Enalapril Powder for Oral Solution

Denver, September 8, 2014—Silvergate Pharmaceuticals, Inc. (www.Silvergatepharma.com), focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Epaned® (Enalapril Maleate Powder for Oral Solution) for the treatment of symptomatic heart failure and the treatment of asymptomatic left ventricular dysfunction (to decrease the rate of development of overt heart failure and to reduce hospitalization for heart failure). These indications are in addition to the prior approval for hypertension (high blood pressure) in patients older than 1 month.1 Read full article “FDA Approves 2 New Indications for Epaned®, the First and Only Enalapril Powder for Oral Solution”

FDA Approves Epaned, a Powder for a Liquid Form of Enalapril for Children and Adults

August 13, 2013
Silvergate Pharmaceuticals, Inc.

FDA Approves Epaned, a Powder for a Liquid Form of Enalapril for Children and Adults

Silvergate Pharmaceuticals Inc. Enables Consistent Dosing For Children

Denver, 13 August 2013— Silvergate Pharmaceuticals Inc, focused on the development and commercialization of innovative and safe medicines for children, today announced that the United States Food and Drug Administration (FDA) approved Epaned™ (enalapril maleate Powder for Oral Solution) to treat hypertension (high blood pressure) in people one month and older. Enalapril is one of the most commonly prescribed medicines in the United States to treat high blood pressure.
Read full article “FDA Approves Epaned, a Powder for a Liquid Form of Enalapril for Children and Adults”